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OBJECTIVE DATA: The purpose of this study was to perform a systematic review and metaanalysis of randomized controlled trials on oral
progesterone compared with placebo or other interventions for preterm birth prevention in singleton pregnancies with previous spon-
taneous preterm birth. The primary outcome was preterm birth at<37 weeks gestation; the secondary outcomes included preterm birth
rate at <34 weeks gestation, neonatal morbidity/death, and maternal side-effects.
STUDY: Searches were performed in PubMed, Scopus, ClinicalTrials.gov, PROSPERO, EMBASE, and the Cochrane Register with the use of
a combination of words related to “preterm birth,” “preterm delivery,” “progesterone,” “progestogens,” and “oral” from inception of each
database to April 2018. Additionally, systematic reviews on progesterone for preterm birth prevention that were identified in our search
were also reviewed for additional studies. We included all randomized trials of asymptomatic singleton gestations with previous spon-
taneous singleton preterm birth that had been randomized to prophylactic treatment with oral progesterone vs placebo, no treatment, or
other preterm birth intervention. Exclusion criteria included quasirandomized trials, trials that involved women with preterm labor/
membrane rupture at the time of randomization or multiple gestations.
STUDY APPRAISAL AND SYNTHESIS METHODS: The risk of bias and quality of evidence were assessed for each study. All analyses were
done with an intention-to-treat approach. The primary outcome was incidence of preterm birth at <37 weeks gestation; the secondary
outcomes included preterm birth at <34 and <28 weeks gestation, maternal adverse events, maternal serum progesterone level, and
neonatal morbidity and death. Summary measures were reported as relative risk or mean difference. I2 >30% was used to identify
heterogeneity.
RESULTS: The search strategy identified 79 distinct studies. Three trials on oral progesterone vs placebo (involved 386 patients: 196 in
oral progesterone and 190 in placebo) met the inclusion criteria; there were no studies on oral progesterone vs other intervention that met
inclusion criteria. Metaanalysis demonstrated a significantly decreased risk of preterm birth at <37 weeks gestation (42% vs 63%;
P¼.0005; relative risk, 0.68; 95% confidence interval, 0.55e0.84), preterm birth at <34 weeks gestation (29% vs 53%; P<.00001;
relative risk, 0.55; 95% confidence interval, 0.43e0.71), and increased gestational age of delivery (mean difference, 1.71 weeks; 95%
confidence interval, 1.11e2.30) with oral progesterone compared with placebo. There was a significantly lower rate of perinatal death (5%
vs 17%; P¼.001; relative risk 0.32; 95% confidence interval, 0.16e0.63), neonatal intensive care admission (relative risk, 0.39; 95%
confidence interval, 0.25e0.61), respiratory distress syndrome (relative risk, 0.21; 95% confidence interval, 0.05e0.93), and higher
birthweight (mean difference, 435.06 g; 95% confidence interval, 324.59e545.52) with oral progesterone. There was a higher rate of
maternal adverse effects with oral progesterone that included dizziness (relative risk, 2.95; 95% confidence interval, 1.47e5.90),
somnolence (relative risk, 2.06; 95% confidence interval, 1.29e3.30), and vaginal dryness (relative risk, 2.37; 95% confidence interval,
1.10e5.11); no serious adverse effects were noted.
CONCLUSION: Oral progesterone appears to be effective for the prevention of recurrent preterm birth and a reduction in perinatal morbidity
and mortality rates in asymptomatic singleton gestations with a history of previous spontaneous preterm birth compared with placebo.
There were also increased adverse effects with oral progesterone therapy compared with placebo, although none were serious. Further
randomized study on oral progesterone compared with other established therapies for the prevention of recurrent preterm birth are
warranted.
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AJOG at a Glance
Why was this study conducted?
This systematic review andmetaanalysis was conducted to evaluate the efﬁcacy of
oral progesterone for the prevention of recurrent preterm birth in randomized
controlled trials. 17-hydroxyprogesterone caproate is currently the only Food and
Drug Administrationeapproved medication for the prevention of recurrent
preterm birth; however, its effectiveness is limited by access, adherence, and
patient-speciﬁc characteristics; thus, alternatives should be explored.
Key ﬁndings
Our metaanalysis demonstrates that oral progesterone is effective in reducing the
risk of preterm birth and perinatal morbidity and death, compared with placebo,
in asymptomatic singleton pregnancies with previous spontaneous preterm birth.
What does this add to what is known?
Previous metaanalyses on progesterone have focused on vaginal progesterone or
17-hydroxyprogesterone caproate; reviews that have included oral progesterone
therapy have either grouped progestogens together and/or grouped indications
for therapy together, thereby limiting the external validity of the ﬁndings. This
review and metaanalysis is unique in its examination of oral progesterone spe-
ciﬁcally for the prevention of recurrent preterm birth; our results suggest that
randomized trials of oral progesterone compared with 17-hydroxyprogesterone
caproate (17OHPC) and vaginal progesterone are warranted.
Systematic Review Obstetricsreterm birth is a leading cause ofP neonatal morbidity and death.
History of previous spontaneous pre-
term birth is 1 of the major risk
factors for preterm birth. Intramus-
cular 17-hydroxyprogesterone caproate
(17OHPC), a synthetic progestin, has
been shown to reduce the risk of recur-
rent preterm birth.1 However, because of
issues that are related to access and side-
effects, adherence to 17OHPC is not
always ideal2,3 and may impact its
effectiveness adversely in the real world.4
A recent metaanalysis also showed that
daily vaginal natural progesterone, either
suppository or gel, is a reasonable, if not
better, alternative to weekly 17OHPC for
the prevention of recurrent preterm
birth.5
Oral natural progesterone has not
been as well-studied for recurrent pre-
term birth prevention. The advantages
of oral micronized progesterone include
increased patient acceptance and
potential adherence and improved access
because no specialty pharmacy is
required. The efﬁcacy of oral progester-
one may be questioned because of a
signiﬁcant ﬁrst-pass effect from hepatic
metabolism,6 although studies outside of2 AJOG MFM MONTH 2019pregnancy have shown similar bioavail-
ability as vaginal administration.7
The purpose of this study was to
perform a systematic review and meta-
analysis of randomized controlled trials
about the use of oral progesterone for the
prevention of recurrent preterm birth in
singleton pregnancies with a history of
spontaneous preterm birth.
Methods
Eligibility criteria, information
sources, search strategy
This metaanalysis was performed ac-
cording to a protocol that was recom-
mended for systematic review.8 Before
data extraction, the review was registered
with the PROSPERO International Pro-
spective Register of Systematic Reviews
(CRD42018095246). The research pro-
tocol was designed a priori, deﬁning
methods for searching the literature,
including examining articles, and
extracting and analyzing data. Searches
were performed in MEDLINE, OVID,
Scopus, ClinicalTrials.gov, the PROS-
PERO International Prospective Register
of Systematic Reviews, EMBASE, and the
Cochrane Central Register of Controlled
Trials with the use of a combination ofkeywords and text words related to
“preterm birth,” “preterm delivery,”
“progesterone,” “progestogens,” and
“oral” from inception of each database to
April 2018. No restrictions for language
or geographic location were applied.
Study selection
We included all RCTs of asymptomatic
singleton gestations with previous
spontaneous singleton preterm birth
who were randomized to prophylactic
treatment with oral progesterone vs
placebo, no treatment, or other preterm
birth intervention (ie, intramuscular
progesterone, cerclage). Exclusion
criteria included quasirandomized trials
(ie, trials in which allocation was done
on the basis of a pseudo-random
sequence, such as odd/even hospital
number or date of birth, alternation) and
trials that involved women with preterm
labor/rupture at the time of randomi-
zation. Trials in women with multiple
gestations were excluded.
Data extraction
All analyses were done with the use of
aggregate data, as reported in original
trials. Authors were contacted for addi-
tional data as needed. The primary
outcome was incidence of preterm birth
at <37 weeks gestation. Secondary out-
comes were preterm birth at <34 weeks
gestation, preterm birth <28 weeks
gestation, maternal adverse events,
serum progesterone levels at 20 and 28
weeks gestation, and neonatal outcomes
that include birthweight (in grams),
admission to neonatal intensive care unit
(NICU), length of stay in NICU (days),
respiratory distress syndrome (RDS;
either transient tachypnea of the
newborn infant or severe RDS), intra-
ventricular hemorrhage (grade 3 or 4),
necrotizing enterocolitis (grade 3 or 4),
neonatal sepsis (culture-proven sepsis),
and perinatal death. Perinatal death was
deﬁned as either fetal death (ie, fetal
death after 20 weeks gestation) or
neonatal death (ie, death of a live born
baby within the ﬁrst 28 days of life). All
authors of the original trials were con-
tacted to obtain missing data, if possible.
All review stages were conducted
independently by 2 reviewers (R.C.B.,
FIGURE 1
Search strategy
Flow diagram of studies identified in the systematic review.
RCT, randomized controlled trial.
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Obstetrics Systematic ReviewL.D.D.) who assessed inclusion criteria,
risk of bias, data extraction, and data
analysis. Disagreements were resolved by
discussion with a third reviewer (G.S.).
Before data extraction, the review was
registered with the PROSPERO Inter-
national Prospective Register of Sys-
tematic Reviews (CRD42018095246).
Assessment of risk of bias
The risk of bias in each included study
was assessed by use of the criteria out-
lined in the Cochrane Handbook for
Systematic Reviews of Interventions.8
Seven domains related to risk of bias
were assessed in each included trial
because there is evidence that these is-
sues are associated with biased estimates
of treatment effect: (1) random sequence
generation, (2) allocation concealment,
(3) blinding of participants and
personnel, (4) blinding of outcome
assessment, (5) incomplete outcome
data, (6) selective reporting, and (7)
other bias. Review authors’ judgments
were categorized as “low risk,” “high
risk,” or “unclear risk” of bias.7
For this review, the quality of evidence
was assessed with the GRADE approach9
to assess the quality of the body of evi-
dence that related to primary and
selected secondary outcomes. GRADE-
pro Guideline Development Tool
(https://gdt.gradepro.org/app/handbook/
handbook.html) was used to import data
from Review Manager (version 5.2; The
Nordic Cochrane Center, Cochrane
Collaboration, Copenhagen, Denmark)
to create a “Summary of Findings” table.
A summary of the intervention effect
and a measure of quality for each of the
aforementioned outcomes was produced
with the GRADE approach. The evi-
dence can be downgraded from “high
quality” by 1 level for serious (or by 2
levels for very serious) limitations,
depending on assessments for risk of
bias, indirectness of evidence, serious
inconsistency, imprecision of effect esti-
mates, or potential publication bias. The
quality of the evidence (and its inter-
pretation) was judged in the following
manner: high quality (further research is
very unlikely to change our conﬁdence in
the estimate of effect), moderate quality
(further research is likely to have anMONTH 2019 AJOG MFM 3
TABLE 1
Characteristics of included randomized trials
Characteristic
Randomized trial
Ashoush et al, 201710 Glover et al, 201111 Rai et al, 200912
Methods Double blind randomized
controlled trial
Double blind randomized
controlled trial
Double blind randomized
controlled trial
Location Egypt United States India
Sample size 205 33 148
Oral progesterone dose 100 mg every 6 hrs until
37 wks gestation (N¼103)
400 mg twice daily until
34 wks gestation (N¼19)
100 mg twice daily until
36 wks gestation (N¼74)
Comparator Placebo (N¼102) Placebo (N¼14) Placebo (N¼74)
Gestational age range
at randomization
14e18 Wks 16e20 Wks 18e24 Wks
Inclusion criteria Singleton gestation 14e18 wks,
previous spontaneous preterm
birth at <37 wks gestation
Singleton gestation <20 wks,
previous spontaneous preterm
birth at 20e36 wks 6 d
Singleton gestation 18e24 wks,
previous spontaneous preterm
birth at 16e36 wks 6 d
Assessment of cervical
length
Cervical length ultrasound
scan at 20 wks gestation
Cervical length ultrasound scan at
least once at <24 wks gestation,
every 2 wks if cervical length was
10e25 mm, weekly for cervical
length <10 mm
Cervical length assessment in
second trimester
Management of short
cervix
Cerclage offered for cervical
length <15 mm
Cerclage offered for cervical
length 5 mm
Not reported
Primary outcome Preterm birth at <37 wks gestation Preterm birth at <37 wks gestation Mean prolongation of pregnancy
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the estimate of effect andmay change the
estimate), low quality (further research
is very likely to have an important
impact on our conﬁdence in the estimate
of effect and is likely to change the esti-
mate), and very low quality (we are very
uncertain about the estimate). The
judgments about quality were justiﬁed,
documented, and incorporated into the
reporting of results for primary and
secondary outcomes.
Data synthesis
The data analysis was completed with
Review Manager software (version 5.3;
The Nordic Cochrane Center, Cochrane
Collaboration). The completed analyses
was then compared and any difference
was resolvedwith reviewof the entire data
and independent analysis. The summary
measures were relative risk (RR) or mean
difference (MD) with 95% of conﬁdence
interval (CI) with the use of the ﬁxed ef-
fects model. I-square (Higgins I2) >30%
was used to identify heterogeneity, in4 AJOG MFM MONTH 2019such cases a random-effects model was
used, as recommended by the Cochrane
Handbook for Systematic Reviews.
Potential publication bias was planned to
be assessed with Begg’s and Egger’s tests.
Probability value of<.05 was considered
statistically signiﬁcant.
Results
Study selection
The search strategy identiﬁed 85 total
reports that represented 79 distinct
studies. Of these 79 studies, 3 met
inclusion criteria for the review
(Figure 1).10e12 Three trials (involving
386 patients: 196 in oral progesterone
and 190 in placebo) met the inclusion
criteria. There were no studies of oral
progesterone compared with other in-
terventions that met inclusion criteria.
Study characteristics
Characteristics of included studies are
given in Table 1. All of the trials
compared oral progesterone with pla-
cebo, although the speciﬁc dosing of oralprogesterone varied by trial. All the trials
included women with singleton gesta-
tion, previous spontaneous preterm
birth, and randomization at <24 weeks
gestation, although the deﬁnition of
previous spontaneous preterm birth
varied (Table 1). All included studies
were double-blind placebo controlled
randomized trials. Management of cer-
vical length screening and short cervix
varied by study. All of the studies per-
formed at least 1 cervical length ultra-
sound scan; 1 study offered history-
indicated cerclage and “rescue” cerclage
for cervical length <15 mm, and
approximately 70% of participants had a
cerclage10; 1 study offered cerclage for
cervical length <5 mm, and none of the
participants had a cerclage11; and 1 study
did cervical length ultrasound scan, but
the criteria for cerclage were not re-
ported, and only 3e4% of the partici-
pants had a cerclage.12 Baseline
characteristics of study population are
presented in Table 2. Regarding the 1
study with >70% of participants with
TABLE 2
Baseline maternal characteristics
Baseline characteristics Trial Oral progesterone Placebo
Maternal age, ya Ashoush et al, 2017 29.34.5 29.53.5
Glover et al, 2011 29.34.7 27.24.9
Rai et al, 2009 26.073.24 25.723.42
Mean gestational age at randomization, wka Ashoush et al, 2017b 15.210.98 15.310.97
Glover et al, 2011 16.92.6 18.22.7
Rai et al, 2009 20.692.83 20.731.78
Race (not white), % Ashoush et al, 2017b 100 % (all North African) 100 % (all North African)
Glover et al, 2011 42.1 50
Rai et al, 2009b 100% (all South Asian 100% (all South Asian)
Previous preterm births, na Ashoush et al, 2017 1.650.63 1.720.65
Glover et al, 2011 2.21.2 1.50.9
Rai et al, 2009 1.210.53 1.310.52
Baseline cervical length, mma Ashoush et al, 2017 25.78.3 23.99.7
Glover et al, 2011 34.96.9 34.04.5
Rai et al, 2009b 28.99 3.751 26.933.489
Cerclage, n (%) Ashoush et al, 2017 70 (72.9) 73 (80.2)
Glover et al, 2011 0 0
Rai et al, 2009b 2 (3) 3 (4)
a Data are given as meanstandard deviation; b Indicates unpublished data provided by authors.
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Risk of bias graph
Assessment of risk of bias graph: Each risk of bias item presented as percentages across all included
studies.
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Obstetrics Systematic Reviewcerclage, 60% of the participants had an
elective cerclage placed, and approxi-
mately 10% of them had a “rescue”
cerclage placed based on ultrasound
scans.10
Risk of bias of included studies
Risk of bias was overall low for all
included studies; they were all double-
blinded placebo-controlled prospective
randomized trials (Figure 2).
Synthesis of results
All outcomes are presented in Table 3,
and key outcomes along with grade of
evidence are presented in the summary
of ﬁndings table (Figure 3). Unpublished
data were provided by 3 of the authors
(D.M., S.A., and S.R.).
Primary outcome
Regarding the primary outcome of this
metaanalysis, all studies reported pre-
term birth at <37 weeks gestation. Twostudies individually found a signiﬁcantly
decreased rate of preterm birth at <37
weeks gestation with oral progesterone
compared with placebo, and meta-
analysis demonstrated a signiﬁcantlydecreased risk of preterm birth at <37
weeks gestation with use of oral proges-
terone compared with placebo (42% vs
63%; P¼.0005; RR, 0.68; 95% CI,
0.55e0.84; Figure 4).10,12MONTH 2019 AJOG MFM 5
TABLE 3
Oral progesterone vs placebo in the prevention of recurrent preterm birth, metaanalysis, and summary of primary
and secondary outcomes
Outcome Trial Oral progesterone Placebo
Relative risk or mean
difference (95%
confidence interval)
Preterm birth
At <37 wks gestation, n/N (%) Ashoush et al, 2017 50/103 (48) 69/102 (67)
Glover et al, 2011 5/19 (26) 8/14 (57)
Rai et al, 2009 29/74 (39) 44/74 (59)
Total 84/196 (42) 121/190 (63) 0.68 (0.55e0.84)a
At <34 wks gestation, n/N (%) Ashoush et al, 2017b 32/103 (31) 61/102 (59)
Glover et al, 2011b 3/19 (15) 3/14 (21)
Rai et al, 2009 22/74 (29) 37/74 (50)
Total 57/196 (29) 101/190 (53) 0.55 (0.43e0.71)a
At <28 wks gestation, n/N (%) Ashoush et al, 2017b 7/103 (7) 11/102 (11)
Glover et al, 2011b 0/19 (0) 0/14 (0)
Rai et al, 2009 0/74 (0) 0/74 (0)
Total 7/196 (4) 14/196 (7) 0.51 (0.22e1.20)
Gestational age at delivery, wkc Ashoush et al, 2017 35.42.7 33.92.9
Glover et al, 2011 372.7 35.93.8
Rai et al, 2009 36.12.7 34.03.3
Mean difference 1.71 (1.11e2.30)a
Birthweight, gc Ashoush et al, 2017 231277 187874
Glover et al, 2011 2830657 2839923
Rai et al, 2009 2400650 1890560
Mean difference 435.06 (324.59e545.52)a
Neonatal intensive care unit admission, n/N (%) Ashoush et al, 2017 22/96 (23) 42/91 (46)
Glover et al, 2011b 3/19 (16) 5/14 (35)
Rai et al, 2009 10/74 (14) 38/74 (51)
Total 35/189 (19) 85/179 (47) 0.39 (0.28e0.55)a
Length of neonatal intensive care unit stay, dc Ashoush et al, 2017 15.45.5 19.55.8
Glover et al, 2011 6.510.5 7.59.0
Rai et al, 2009bd 2.10 (50.62) 5.05 (121.34)
Mean difference -3.93 (-5.50e-2.35)
Perinatal death, n/N (%) Ashoush et al, 2017 7/96 (7) 23/91 (25)
Glover et al, 2011b 0/19 (0) 0/14 (0)
Rai et al, 2009 3/74 (4) 7/74 (9)
Total 10/189 (5) 30/179 (17) 0.32 (0.16e0.63)a
Respiratory distress syndrome, n/N (%) Ashoush et al, 2017 21/96 (22) 39/91 (43)
Glover et al, 2011 0/19 (0) 3/14 (21)
Rai et al, 2009 3/74 (4) 31/74 (42)
Total 24/189 (13) 73/179 (41) 0.21 (0.05e0.93)a
Intraventricular hemorrhage, n/N (%) Ashoush et al, 2017 8/96 (8) 11/91 (12) 0.69 (0.29e1.64)
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TABLE 3
Oral progesterone vs placebo in the prevention of recurrent preterm birth, metaanalysis, and summary of primary
and secondary outcomes (continued)
Outcome Trial Oral progesterone Placebo
Relative risk or mean
difference (95%
confidence interval)
Necrotizing enterocolitis, n/N (%) Ashoush et al, 2017 5/96 (5) 9/91 (10) 0.53 (0.18e1.51)
Neonatal sepsis, n/N (%) Rai et al, 2009b 0/74 (0) 2/74 (3) 0.20 (0.01e4.10)
Serum progesterone, ng/mLc Ashoush et al, 2017 34.53.8 17.63.3
Glover et al, 2011 122.661.8 90.138.7
Mean difference 16.91 (15.89e17.93)a
Dizziness, n/N (%) Ashoush et al, 2017 28/96 (29) 9/91 (10)
Glover et al, 2011 0/19 (0) 0/14 (0)
Total 28/115 (24) 9/105 (9) 2.95 (1.47e5.90)a
Constipation, n/N (%) Ashoush et al, 2017 21/96 (22) 13/91 (14)
Glover et al, 2011 0/19 (0) 0/19 (0)
Total 21/115 (18) 13/105 (12) 1.53 (0.82e2.87)
Somnolence, n/N (%) Ashoush et al, 2017 40/96 (41) 18/91 (19)
Glover et al, 2011 0/19 (0) 0/14 (0)
Rai et al, 2009 1/74 (1) 1/74 (1)
Total 41/189 (22) 19/179 (11) 2.06 (1.29e3.30)a
Vaginal dryness, n/N (%) Ashoush et al, 2017 20/96 (21) 8/91 (9)
Glover et al, 2011 0/19 (0) 0/14 (0)
Total 20/115 (17) 8/105 (8) 2.37 (1.10e5.11)a
Acne, n/N (%) Glover et al, 2011 0/19 (0) 0/14 (0)
Rai et al, 2009 2/74 (3) 1/74 (1)
Total 2/93 (2) 1/88 (1) 2.00 (0.19e21.58)
Esophageal reflux, n/N (%) Glover et al, 2011 0/19 (0) 0/14 (0)
Rai et al, 2009 2/74 (3) 0/74 (0)
Total 2/93 (2) 0/88 (0) 5.00 (0.24e102.40)
Headache, n/N (%) Glover et al, 2011 0/19 (0) 0/14 (0)
Rai et al, 2009 0/74 (0) 1/74 (1)
Total 0/93 (0) 1/88 (1) 0.33 (0.01e8.05)
Depression, n/N (%) Glover et al, 2011 0/19 (0) 0/14 (0)
Rai et al, 2009 0/74 (0) 4/74 (5)
Total 0/93 (0) 4/88 (5) 0.11 (0.01e2.03)
a Indicates P<.05; b Indicates unpublished data provided by authors10e12; c Data are presented as meanstandard deviation; d Data are presented median (interquartile range).
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Preterm birth. All included studies re-
ported on preterm birth-related out-
comes. Regarding secondary outcomes,
metaanalysis demonstrated a signiﬁ-
cantly reduced risk of preterm birth at<34 weeks gestation (29% vs 53%;
P<.00001; RR, 0.55; 95% CI, 0.43e0.71)
and increased gestational age of delivery
(MD, 1.71 weeks gestation; 95% CI,
1.11e2.30), but not of preterm birth at
<28 weeks gestation (RR, 0.51; 95% CI,0.22e1.20) with oral progesterone
compared with placebo. Ashoush et al10
reported any delivery at <28 weeks
gestation as “miscarriage” because the
neonates are not able to be resuscitated,
thus most analyses exclude thoseMONTH 2019 AJOG MFM 7
FIGURE 3
Summary of findings
These findings compare oral progesterone with placebo for the prevention of recurrent preterm birth.
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FIGURE 4
Oral progesterone vs placebo metaanalysis
Forest plots of outcomes of preterm birth at A, <37 and B, <34 weeks gestation.
CI, confidence interval; M-H, Mantel-Haenszel.
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Obstetrics Systematic Reviewdeliveries (n¼187); however, the authors
provided data on incidence of deliveries
at 20e28, 28e34, 34e37, and >37
weeks gestation; thus, the number of
participants for these outcomes is 205.
Neonatal outcomes. Regarding neonatal
outcomes, I2 was >30% with certain
outcomes. Oral progesterone therapy
resulted in a signiﬁcantly lower rate of
perinatal death (5% vs 17%; P¼.001; RR,
0.32; 95% CI, 0.16e0.63; studies¼3;
I2¼0%), higher birth weight (MD,
435.06 g; 95% CI, 324.59e545.52;
studies¼3; I2¼32%), lower rate of
neonatal intensive care admission (RR,
0.39; 95% CI, 0.25e0.61; studies¼3;
I2¼29%; P¼.25), and shorter NICU stay
(MD, 3.93 days; 95%CI,e5.50 toe2.35;
studies¼2; I2¼0). Of note the Rai et al12
reported NICU stay in median; thus, it
was not included in quantitative meta-
analysis (Table 3). Regarding speciﬁc
neonatal morbidities, there was asigniﬁcantly reduced rate of RDS (RR,
0.21; 95% CI, 0.05e0.93; studies¼3;
I2¼78%; P¼.01) in oral progesterone
compared with placebo. Regarding other
neonatal morbidities, there was not a
signiﬁcant difference found in rates of
intraventricular hemorrhage (RR, 0.69;
95% CI, 0.29e1.64; studies¼ 1), necro-
tizing enterocolitis (RR, 0.53; 95% CI,
0.18e1.51; studies¼1), or neonatal
sepsis (RR, 0.20; 95% CI, 0.01e4.10;
studies¼1).
Maternal effects. There was a signiﬁcantly
higher rate of maternal side-effects
with oral progesterone compared with
placebo, although no serious adverse
effects were reported. These included
a higher rate of dizziness (RR, 2.95;
95% CI, 1.47e5.90; studies¼2), som-
nolence (RR, 2.06; 95% CI, 1.29e3.30;
studies¼3), and vaginal dryness (RR,
2.37; 95% CI, 1.10e5.11; studies¼2;
Table 3).Serum progesterone.Use of oral proges-
terone was associated with a signiﬁcantly
higher maternal serum progesterone
level at 28 weeks gestation compared
with placebo (MD, 16.91 ng/mL; 95%
CI, 15.89e17.93; studies¼2; Table 3).
Sensitivity analyses. Given the high rate
of concurrent cerclage use in 1 study,10
although equal in both groups, a post-
hoc sensitivity analysis was performed
for outcomes of preterm birth at <37
and <34 weeks gestation excluding this
study. Oral progesterone remained
associated with a reduced risk of preterm
birth at <37 weeks gestation (RR, 0.62;
95% CI, 0.45e0.86) and preterm birth
at <34 weeks gestation (RR, 0.61; 95%
CI, 0.41e0.91).
Comment
Main ﬁndings
This review and metaanalysis suggests
that oral progesterone is effective for theMONTH 2019 AJOG MFM 9
TABLE 4
Description of 4 randomized studies with oral progesterone in preterm birth prevention that were excluded from
metaanalysis
Characteristic
Randomized trial
Noblot et al, 199122 Ndoni et al, 201020 Choudhary et al, 201421 Pustotina, 201823
Methods Double blind randomized
controlled trial
Randomized control study Double blind randomized
controlled trial
Randomized trial, open label
with crossover after 1 week
of therapy in randomized
assignment
Location France Albania India Russia
Sample size 44 121 90 95
Inclusion
criteria
Pregnant patients (including
multiples) underwent tocolytic
therapy for threated preterm labor;
patients with preterm premature
rupture of membranes at <32 wks
gestation or previous tocolytic
therapy excluded
Pregnant patients hospitalized
at high risk for preterm delivery
Singletons at 24e34 wks
gestation recruited after
successful tocolysis
with nifedipine
Singleton gestation, cervical
length 25 mm with or
without symptoms of
preterm labor/miscarriage
(60 symptomatic at
randomization)
Oral progesterone
dose
400 mg every 6 hrs for 24 hrs,
every 8 hrs for 24 hrs, 300 mg
every 8 hrs daily; micronized
progesterone (Utrogestan)
Dose not specified, micronized
oral progesterone (Utrogestan)
200 mg micronized
progesterone daily
Oral progesterone 400 mg
daily
Comparator Placebo Daily 17 hydroxy-progesterone
caproate and placebo
Placebo 17OHP 250 mg
intramuscularly weekly
OR vaginal progesterone
400 mg daily OR
dydrogesterone
30 mg daily
Gestational
age range at
randomization
<35 Wks 15e22 Wks 24e64 Wks 15e24 Wks
Primary
outcome
Latency to delivery:
not different between groups
Not specified (abstract only),
preterm labor and perinatal
outcomes reported as improved
in 17OHPC and oral
progesterone vs placebo, but
not compared with each other
Latency to delivery:
improved in oral
progesterone vs placebo
Not specified; oral
progesterone not directly
compared with other
formulations
Boelig et al. Oral progesterone for preterm birth prevention. AJOG MFM 2019.
Systematic Review Obstetricsprevention of recurrent preterm birth
and reduction in perinatal morbidity
and mortality rates in asymptomatic
singleton gestations with a history of
spontaneous preterm birth. Speciﬁcally,
we found a statistically signiﬁcant
reduction in preterm birth at <37 and
<34 weeks gestation, perinatal deaths,
NICU admission, and RDS. Notably,
there were also increased adverse
effects with oral progesterone therapy
compared with placebo, although no
serious adverse effects were noted.
Quality of evidence
Quality of evidence for primary outcome
and key selected secondary outcomes10 AJOG MFM MONTH 2019was generally low to moderate, with
some deduction for wide conﬁdence
interval or limited event number
(Table 3). Quality of evidence for speciﬁc
neonatal morbidities (ie, RDS, neonatal
enterocolitis) was low to very low
because of wide conﬁdence interval,
heterogeneity, and limited events. Simi-
larly, quality of evidence for maternal
adverse effects was low to very low
because of wide conﬁdence interval and
limited number of events and limited
studies.
Strengths and limitations
One of the strengths of this study is the
assessment of a speciﬁc formulation ofprogesterone (oral) in a speciﬁc high-
risk population (previous spontaneous
preterm birth) that allows for the clinical
application of these results. This is the
only metaanalysis of oral progesterone
compared with placebo in this speciﬁc
population to have this many patients
included. Other metaanalyses have
either combined various progesterone
formulations/routes of administration
together13e16 or included studies with
variable inclusion criteria/preterm birth
risks,17 thus limiting the clinical utility of
the results. Additionally, the quality of
evidence for the reduction in early pre-
term birth (<34 weeks gestation) for
some other key outcomes was moderate
Obstetrics Systematic Review(Figure 3). Finally, the evaluation of
serum progesterone and difference in
treated vs placebo provides biologic
plausibility to mechanism of action of
oral progesterone in pregnancy and its
ability to have a systemic effect.
There are a few limitations. This
metaanalysis includes only 3 studies, 1 of
which was a small pilot study. Because of
the limited number of studies, publica-
tion bias was not assessed. The dosing of
oral progesterone varied by each study,
with the lowest regimen being 100 mg
twice daily; the optimal dose for preterm
birth prevention could not be concluded
with this analysis. Because of limited
sample size and event number, the
quality of evidence for speciﬁc neonatal
morbidities and maternal adverse events
was low to very low. The study popula-
tion between studies was heterogeneous
that was related speciﬁcally to the inci-
dence and management of short cervix.
In the largest study, approximately 70%
of participants had a cerclage, which
were primarily placed due to obstetric
history and even between groups; in the
other 2 studies, cerclage use was zero to
minimal. Thus, 1 randomized trial
demonstrated beneﬁt of oral progester-
one compared with placebo even with
70% of participants with cerclage in each
group; however, because this is not an
individual patient data analysis, the
speciﬁc efﬁcacy of oral progesterone in
normal vs short cervical length cannot
be concluded. Oral progesterone
remained beneﬁcial in preterm birth
prevention, even with the exclusion of
this 1 study in our post hoc sensitivity
analysis. Finally, neonatal outcomes
depend on the resources and technology
available; therefore, outcomes, such as
perinatal death in other countries or in
studies done over 5 or 10 years ago, may
not be as applicable in the United States
in the current day.
Comparison with existing literature
Although this analysis is unique in its
focus on oral progesterone for a speciﬁc
indication, our results are consistent
with other reviews that have demon-
strated efﬁcacy in oral progesterone for
preterm birth prevention in general.
One recent review that included oralprogesterone combined it with other
progestogens to evaluate efﬁcacy in
different clinical scenarios.13 Another
metaanalysis evaluated progesterone
efﬁcacy by route; thus, oral progesterone
was evaluated separately, and it was
found that oral progesterone was effec-
tive in preterm birth prevention. How-
ever, that analysis is limited because
indication for therapy was varied
(included symptomatic and asymptom-
atic patients), and the most recent and
largest randomized study10 was not
included.14 A recent metaanalysis eval-
uated progesterone by route and indi-
cation but did not include the most
recent, large randomized study and did
not examine the number of outcomes
reported here.15 The conclusion of that
metaanalysis that used just 2 trials11,12
similarly identiﬁed a reduction in pre-
term birth at <34 weeks gestation but
not a reduction in preterm birth at <37
weeks gestation or in perinatal death.15 A
Cochrane review on progesterone for
preterm birth prevention found that
progesterone overall was effective in
preterm birth prevention compared with
placebo and improved neonatal
morbidity and mortality rates; however,
all progesterone formulations were
combined, and a conclusion on efﬁcacy
by route/formulation could not be
made.16 The combination of progesto-
gen formulations in metaanalyses is
problematic because micronized proges-
terone that is administered vaginally and
orally may have different systemic vs local
uterine/cervical effects17,18 and because
natural progesterone and 17OHPC are
distinct in their mechanism of action and
indication for use.19 The combination of
indications for therapy is also problem-
atic because clinically an asymptomatic
patient in the second trimester has a
different risk for preterm birth and
different clinical treatment than a patient
with preterm labor or preterm premature
rupture of membranes.
There were a total of 7 completed
randomized trials on oral progesterone
for preterm birth prevention that were
identiﬁed in our search strategy; Table 4
includes characteristics of excluded
randomized studies. One study, in
abstract form only, randomized “high-risk” participants in the second trimester
to daily 17OHPC (n¼52), oral proges-
terone (n¼43), or placebo (n¼26),
which identiﬁed that both 17OHPC and
oral progesterone were superior to pla-
cebo in the prevention of preterm labor
and improvement of perinatal outcome,
but no difference when oral progester-
one is compared with 17OHPC.20 This
study was not included in our analysis
because the inclusion criteria were not
speciﬁed, which included previous pre-
term birth or absence of symptoms, and
the authors did not respond to our
request for additional information;
however, the ﬁndings are consistent with
our review that identiﬁed the beneﬁt of
oral progesterone compared with pla-
cebo. There were 2 other randomized
studies that evaluated oral progesterone
in the setting of preterm labor or
halted preterm labor; 1 study found that
oral progesterone improved latency
compared with placebo,21 and 1 study
found that oral progesterone and pla-
cebo were equivalent in latency.22
Finally, 1 study evaluated oral proges-
terone, 17OHPC, and vaginal proges-
terone compared with cerclage in
women with a short cervix and found
that only vaginal progesterone was
effective; this study is difﬁcult to inter-
pret because they included symptomatic
and asymptomatic participants.23 The
efﬁcacy of progesterone in the setting of
preterm labor or halted preterm labor is
different from its efﬁcacy in asymp-
tomatic high-risk individuals16; there-
fore, we did not combine all randomized
trials on oral progesterone in this review.
There is currently 1 ongoing ran-
domized controlled trial on oral pro-
gesterone for prevention of preterm
birth (NCT03428685). The inclusion
criteria includes all singletons, so it is not
speciﬁc to those with previous preterm
birth, and it also compares oral proges-
terone with placebo.
Our review is consistent with a pre-
vious randomized trials and systemic
review by identifying that oral proges-
terone is effective in preterm birth pre-
vention, although the inclusion criteria
for those previous reports is distinct
from ours.14 This study builds on exist-
ing literature with additional trial dataMONTH 2019 AJOG MFM 11
Systematic Review Obstetricsand by identifying a speciﬁc patient
population for which oral progesterone
improves preterm birth rate and
neonatal morbidity and mortality rates.
Implications
This review demonstrates the need for
further head-to-head clinical trials on
oral progesterone for the prevention of
recurrent preterm birth. Themechanism
of action of progesterone, in general, in
preterm birth prevention is unclear. It
likely plays a role in inﬂammatory
pathways, uterine relaxation, and cervi-
cal modeling.24,25 Although oral pro-
gesterone does undergo an hepatic ﬁrst-
pass effect,6 based on this review, that
does not preclude its efﬁcacy; there is still
a measurable increase in serum proges-
terone even with elevated endogenous
progesterone in pregnancy and a reduc-
tion in preterm birth.
The use of serum progesterone as a
potential pharmacokinetic and phar-
macodynamics endpoint in oral proges-
terone allows for detailed studies into
optimal dosing and assessment of
threshold serum levels for therapeutic
efﬁcacy. Dosing in both vaginal proges-
terone and 17OHPC was derived
empirically, and doses have yet to be
modiﬁed based on pharmacologic prin-
ciples to improve efﬁcacy. The potential
for oral progesterone to be studied in this
way allows for a therapy that can be
monitored with a standard laboratory
assay and adjusted to maximize its
beneﬁt.
Head-to-head comparisons of oral
progesterone against other formulations
of progesterone in asymptomatic
singleton pregnancies with previous
spontaneous preterm birth are war-
ranted to compare efﬁcacy in prevention
of preterm birth and neonatal
morbidity/death, adherence, and side-
effects. Currently, 17OHPC is the only
medication approved for the prevention
of recurrent preterm birth; however,
its use is limited by patient charac-
teristics,26,27 access,28 high rate of
side-effect,1 and adherence.28,29 Oral
progesterone is a more affordable and
potentially more acceptable alternative
for patients. Oral progesterone appears
to be effective and well-accepted and12 AJOG MFM MONTH 2019warrants further study in prospective
randomized trials. -
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